Agoracom: Small Cap Investment - Zenith Epigenetics - Re: AGM - Jan 7, 2016

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: AGM - Jan 7, 2016 - Details

in response to

AGM - Jan 7, 2016 - Details

masila

posted on Jan 08, 2016 01:38PM

Thanks Masila. You rock! My favorite part:

"Q: Future of ZCC, especially what will be done with revenue streams?

A: Dividends, Dividends, Dividends. We aren’t contemplating any further investments. We already have ZEL and RVX. There’s 20 years of development effort at those two alone. We have our hands full."